Skip to main content

Clinical trial LUMINOSITY

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Organ Lung
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor AbbVie
EudraCT Identifier 2018-001772-38
Last update